New insights in the treatment of nontuberculous mycobacterial pulmonary disease


Nontuberculous mycobacteria (NTM) are increasingly recognized as important opportunistic pathogens of humans. Chronic pulmonary infections are the most frequent diseases associated with NTM, particularly with Mycobacterium avium complex (MAC) and M. abscessus bacteria. This disease can manifest as a fibro-cavitary disease, mostly in patients with pre-existing pulmonary diseases or as a nodular/bronchiectatic disease, typically in elderly patients without underlying pulmonary diseases. In the latter group, subtle defects of mucociliairy clearance and T-cell immunity have been suggested to underlie susceptibility to NTM disease [1].

Currently recommended antibiotic treatment regimens are presented in Table 1. On average, 50 (M. abscessus) to 70% MAC patients who tolerate recommended regimens achieve prolonged culture conversion [2]. This grave situation has recently led to a series of clinical and preclinical studies aiming to optimize antibiotic treatment of NTM pulmonary disease (NTM-PD).

Click here to read the full article in Future Microbiology.

Interested in Nontuberculous mycobacteria? Read our conference report covering the Papworth symposium on nontuberculosis mycobacteria (NTM) infections, featuring Jakko van Ingen .

Leave A Comment